Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Potassium bicarbonate/potassium citrate - Advicenne

Drug Profile

Potassium bicarbonate/potassium citrate - Advicenne

Alternative Names: ADV 7103; Potassium citrate monohydrated/potassium hydrogen carbonate; Potassium citrate/potassium bicarbonate; Potassium hydrogen carbonate/potassium citrate monohydrated; Potassium-bicarbonate/potassium-citrate-Advicenne

Latest Information Update: 18 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advicenne
  • Class Alkalinising agents; Citrates; Electrolytes; Potassium compounds; Small molecules; Urologics
  • Mechanism of Action Electrolyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Kidney disorders
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Kidney disorders
  • Phase II/III Cystinuria

Most Recent Events

  • 21 Aug 2019 Advicenne Pharma initiates an extension to phase IIIb ARENA 2 trial for Kidney disorders (distal renal tubular acidosis) (In infants, In children, In adolescents, In adults) in USA (PO) (NCT03831152)
  • 21 Jun 2019 Advicenne completes phase-III clinical trials in Kidney disorders (In adolescents, In children, In infants, In adults) in United Kingdom, Spain, Serbia, Slovakia, France, Belgium (PO) (EudraCT2013-003828-36)
  • 12 Mar 2019 Preregistration for Kidney disorders (In adolescents, In children, In infants, In adults) in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top